The present disclosure is based on a surprising finding that a pH sensitive
modified release dosage form is a suitable platform for trazodone therapy. Herein is described a pH sensitive
modified release dosage form for once-a-day
oral administration of trazodone, or a derivative thereof, comprising from 20% to 50% by weight of the trazodone or the derivative thereof, and from 10% to 80% of a release modifying
excipient, which is a hydrogel-forming
excipient. The present disclosure is also based on a surprising finding that dosage forms comprising trazodone have particular
particle size distribution features that are advantageous for uniform release properties, even upon
subdivision. In one such embodiment, less than 35% of the particles are 355μm to 500μm, greater than 5% of the particles are 250μm to 355μm, greater 2% of the particles are 75μm to 150μm, and greater than 5% of the particles are less than 38μm.